Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00027729 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00027729 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer |
| Official title | Phase I/II Study of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological |
| Interventions | etaracizumab |
| Start date | Jun 1, 2001 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: